Georgia's Online Cancer Information Center

Search Trials

All Cancer Clinical Trials in Georgia

Search Trials
All Cancer Clinical Trials
Clinical Trial data last updated Oct 15, 2019.
1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors
Cancer Type
Eye Cancer
NCI ID
NCT01930968
Protocol IDs
IRB0003943
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Cancer Type
NCI ID
NCT03737994
Protocol IDs
NRG-LU003
NRG-LU003
NCI-2018-02486
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCI ID
NCT01503632
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03384914
Protocol IDs
MCC-19117
NCI-2018-00290
A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type
Quality of Life
NCI ID
NCT00948636
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT00668421
Protocol IDs
104
NCI-2012-00298
A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03260491
Protocol IDs
U31402-A-U102
NCI-2018-00060
2017-000543-41
A Multicenter, Open-Label Phase 1b / 2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT02501096
Protocol IDs
E7080-A001-111
NCI-2016-00529
A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT01143181
Protocol IDs
CMX001-350
1986
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus
Cancer Type
NCI ID
NCT01787656
Protocol IDs
USA-MCI GON-1.04
NCI-2015-00690
13-005
A Phase 1 / 2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed / Refractory Chronic Lymphocytic Leukemia
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03624036
Protocol IDs
KTE-C19-108
NCI-2018-02958
2018-001923-38
A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
A Phase 1 / 2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR / HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02716116
Protocol IDs
AP32788-15-101
NCI-2016-00587
U1111-1217-7205
A Phase 1 / 2 Study of VX15 / 2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03320330
Protocol IDs
ADVL1614
ADVL1614
NCI-2017-01103
A Phase 1 / 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02393248
Protocol IDs
INCB 54828-101
NCI-2015-00611
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Cancer Type
NCI ID
NCT01089101
Protocol IDs
PBTC-029
PBTC-029
NCI-2012-03173
CDR667932
PBTC-029B
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02732275
Protocol IDs
DS3201-A-J101
NCI-2019-00366
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Endometrial Cancer
NCI ID
NCT03517488
Protocol IDs
XmAb20717-01
NCI-2018-00935
DUET-2
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Lung Cancer
NCI ID
NCT03752398
Protocol IDs
XmAb23104-01
NCI-2019-00828
DUET-3
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03319940
Protocol IDs
20160323
NCI-2017-02043
A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type
Lung Cancer, Prostate Cancer , Unknown Primary
NCI ID
NCT03799003
Protocol IDs
1951-CL-0101
NCI-2019-02414
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Cancer Type
NCI ID
NCT02561988
Protocol IDs
BLU-285-2101
NCI-2016-00075
2015-001661-12
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Head and Neck Cancer, Lung Cancer
NCI ID
NCT03329950
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02890329
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03030378
Protocol IDs
10061
10061
NCI-2017-00091
HCC 17-003
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02897375
Protocol IDs
Winship3263-16
NCI-2016-01037
IRB00089583
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02323880
Protocol IDs
ADVL1414
NCI-2014-02410
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Chondrosarcoma
NCI ID
NCT02601937
Protocol IDs
EZH-102
NCI-2015-02224
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCI ID
NCT03726333
Protocol IDs
B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03555955
Protocol IDs
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03415126
Protocol IDs
ASN007-101
NCI-2018-00820
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Cancer Type
Unknown Primary
NCI ID
NCT02587598
Protocol IDs
INCB 53914-101
NCI-2015-01975
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02658890
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03357627
Protocol IDs
C34008
NCI-2018-00464
2017-002872-14
U1111-1203-9951
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Adults With Head and Neck Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03937141
Protocol IDs
ADU-CL-20
NCI-2019-04759
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Type
Lymphoma
NCI ID
NCT03589469
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03141684
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
A Phase 2 Study of Lenvatinib in Combination with Radioactive Iodine Therapy in Patients with Progressive RAI-Sensitive Differentiated Thyroid Cancer
Cancer Type
Thyroid Cancer
NCI ID
NCT03506048
Protocol IDs
Winship4271-18
NCI-2018-00144
IRB00101617
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04022343
Protocol IDs
Winship4643-19
NCI-2019-02253
IRB00110583
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Cancer Type
NCI ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02718300
Protocol IDs
INCB 50465-201
NCI-2016-01146
A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT03565991
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT02935634
Protocol IDs
CA018-003
NCI-2017-00025
2016-002807-24
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03361748
Protocol IDs
BB2121-MM-001
NCI-2017-02488
U1111-1202-5554
2017-002245-29
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03915951
Protocol IDs
ARRAY-818-202
NCI-2019-02644
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCI ID
NCT03397394
Protocol IDs
CO-338-085
NCI-2018-01112
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03846427
Protocol IDs
BGB-3111-214 (MAGNOLIA)
NCI-2019-01421
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03706365
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03673501
Protocol IDs
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03651128
Protocol IDs
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03395197
Protocol IDs
C3441021
NCI-2018-01651
TALAPRO-2
2017-003295-31
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
A Phase I / II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and / or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCI ID
NCT03370276
Protocol IDs
MCC-19178
NCI-2017-02373
A Phase I / II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03739619
Protocol IDs
Winship4388-18
NCI-2018-02221
IRB00104033
A Phase I / II Study of Ixazomib and Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03323151
Protocol IDs
PrE0404
NCI-2017-02399
X16077
A Phase I / II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT02713386
Protocol IDs
Treatment Sites (6)
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
A Phase I / II Study of SEL24 in Patients With Acute Myeloid Leukemia
Cancer Type
NCI ID
NCT03008187
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase I / II Study of Trifluridine / Tipiracil (TAS102) in Combination with Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Cancer Type
Pancreatic Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children with Recurrent or Refractory Malignant Brain Tumors
Cancer Type
Brain Cancer
NCI ID
NCT03387020
Protocol IDs
PBTC-050
PBTC-050
NCI-2017-02079
A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed / Refractory Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03332667
Protocol IDs
NANT2017-01
NCI-2018-01160
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03650491
Protocol IDs
FOR46-002
NCI-2018-02600
A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT02359929
Protocol IDs
EPIC2014-MSC002
NCI-2015-00170
EPIC-MSC002
A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03327857
Protocol IDs
2017.002.01
NCI-2018-01343
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT02992522
Protocol IDs
OSU-16187
NCI-2016-01723
2016C0150
A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT02567422
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors
Cancer Type
Brain Cancer
NCI ID
NCT02502708
Protocol IDs
NLG2105
NCI-2015-01872
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Cancer Type
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT01614197
Protocol IDs
T2014-001
NCI-2012-01493
T2008-004
A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT02632396
Protocol IDs
Winship2839-15
NCI-2015-01943
IRB00076016
Winship2839-15 (X16058)
X16058
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT02921256
Protocol IDs
Treatment Sites (1)
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients with Untreated Mantle Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT03872180
Protocol IDs
Winship4363-18
NCI-2018-00995
IRB00102827
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT03691493
Protocol IDs
Winship4472-18
NCI-2018-02000
IRB00105944
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCI ID
NCT03698019
Protocol IDs
Treatment Sites (1)
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer Type
Lung Cancer
NCI ID
NCT03971474
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02396134
Protocol IDs
13494
NCI-2015-00283
118814
121375
119250
118207
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Cancer Type
Ovarian Cancer
NCI ID
NCT03602586
Protocol IDs
NRG-GY016
NRG-GY016
NCI-2018-01561
A Phase II Study of Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Germ Cell Tumor, Penile Cancer, Prostate Cancer
NCI ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
A Phase II Study of Olaparib plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT02899728
Protocol IDs
9974
9974
NCI-2016-01363
TBD
s16-01472
A Phase II Study of Rucaparib in Patients with Genomic LOH High and / or Deleterious BRCA1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Cancer Type
Lung Cancer
NCI ID
NCT03845296
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02574728
Protocol IDs
AFLACST1502
NCI-2015-01637
IRB00082488
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN Who Have Failed Platinum Based Therapy
Cancer Type
Head and Neck Cancer, Oral Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03371719
Protocol IDs
Treatment Sites (15)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555